Asthma Management Guidelines

Initial Assessment and Classification

The American Academy of Family Physicians recommends determining asthma severity based on symptom frequency, with daily symptoms indicating persistent asthma requiring controller therapy 1
Nighttime awakenings more than 2 nights per month suggests need for anti-inflammatory treatment, according to the American Academy of Family Physicians 1
Using short-acting beta-agonist (SABA) more than twice weekly (excluding exercise-induced symptoms) indicates inadequate control and need for controller initiation or intensification, as stated by the American Academy of Family Physicians 1

For patients with mild persistent asthma, the American Academy of Family Physicians recommends low-dose inhaled corticosteroids (ICS) daily as the preferred first-line controller 1
For patients with moderate persistent asthma, the American Academy of Family Physicians suggests adding a long-acting beta-agonist (LABA) to low-dose ICS, or increasing to medium-dose ICS alone, with both options given equal weight 1
The American Academy of Family Physicians warns that LABAs must never be used as monotherapy, as they increase risk of asthma exacerbations and death when used alone 1

The American Academy of Family Physicians recommends oral systemic corticosteroids for moderate to severe exacerbations 1
High-dose nebulized beta-agonists are recommended for acute symptoms, according to the American Academy of Family Physicians 1

The American Academy of Family Physicians states that SABA use more than twice weekly (excluding exercise prophylaxis) indicates need for treatment intensification 1
Nighttime awakenings more than twice monthly also indicate need for treatment intensification, as stated by the American Academy of Family Physicians 1

The American Academy of Family Physicians warns to never use LABA without concurrent ICS, as this significantly increases mortality risk 1
The American Academy of Family Physicians also warns to not delay ICS initiation in persistent asthma, as early intervention improves long-term outcomes 2

The Journal of Allergy and Clinical Immunology recommends slow inhalation (3-5 seconds) followed by 10-second breath-hold when using metered-dose inhalers (MDI) 3
The Journal of Allergy and Clinical Immunology also recommends rapid, deep inhalation (1-2 seconds) when using dry powder inhalers 3

The American Academy of Family Physicians recommends addressing conditions that worsen asthma control, such as allergic rhinitis and sinusitis, and gastroesophageal reflux disease 4
Annual influenza vaccination is recommended for all patients with persistent asthma, according to the American Academy of Family Physicians 4

The American Journal of Respiratory and Critical Care Medicine states that the dose-response curve for ICS is relatively flat, with high doses providing minimal additional benefit over moderate doses but increasing systemic side effects 5
The American Journal of Respiratory and Critical Care Medicine recommends adding a second controller (LABA, LTRA, or LAMA) instead of escalating ICS to high doses 5

Inhaled corticosteroids (ICS) are the most consistently effective long-term control medication at all steps of care for persistent asthma, superior to any other single controller medication in both children and adults, according to the American Academy of Allergy, Asthma, and Immunology 6
ICS improve asthma control more effectively than leukotriene receptor antagonists or any other single long-term control medication, as recommended by the American College of Allergy, Asthma, and Immunology 6
Inhaled corticosteroids reduce both impairment and risk of exacerbations more effectively than alternatives, as stated by the American Thoracic Society 6

Doxofylline belongs to the methylxanthine class, similar to theophylline, which guidelines explicitly state is not recommended as first-line therapy, according to the National Asthma Education and Prevention Program 7, 8

Studies comparing LTRAs to ICS showed most outcome measures "significantly and clearly favored inhaled corticosteroids", as reported by the American Academy of Allergy, Asthma, and Immunology 9, 10
Even long-acting beta-agonists (LABAs) showed significantly more treatment failures (24% vs 6%) and exacerbations (20% vs 7%) when used as monotherapy compared to ICS, according to the Global Initiative for Asthma 9, 10

If asthma remains uncontrolled on low-dose ICS alone, preferred options are adding LABA or increasing ICS dose, as recommended by the American College of Chest Physicians 8
Doxofylline may be considered as an alternative add-on agent (similar to montelukast or theophylline) but is not preferred over LABA, according to the European Respiratory Society 8

Never use doxofylline as monotherapy in persistent asthma—this contradicts established guidelines prioritizing ICS, as stated by the American Thoracic Society 6, 9, 10

Evaluate FEV1 and asthma control at 4-6 week intervals, as recommended by the National Asthma Education and Prevention Program 7, 8